AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22487908 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic instruments
Number of subjects: 200
Study 21619701 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) injections at a pharmacologic dose of 0.3 mg/kg/week
Number of subjects: 34
Study 21619701 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 34
Study 18622302 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (younger patients)
Number of subjects: 260
Study 18622302 — intervention group
Group type: COMPARATOR
Intervention: Group B (older patients)
Number of subjects: 260
Study 16118650 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg vitamin C supplementation
Number of subjects: 244
Study 16118650 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg vitamin C supplementation
Number of subjects: 244
Study 16118650 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 244
Study 14501606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 90 mg
Number of subjects: 160
Study 14501606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg
Number of subjects: 160
Study 14501606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 14501606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene (all doses)
Number of subjects: 160
Study 11740194 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (PRO)
Number of subjects: 30
Study 11740194 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise (PRE)
Number of subjects: 30
Study 11740194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (PRO-PRE)
Number of subjects: 30
Study 9757959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular methotrexate 50 mg/m2
Number of subjects: 20
Study 9757959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular methotrexate 60 mg/m2
Number of subjects: 20
Study 9757959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular methotrexate (both dosages)
Number of subjects: 20
Study 8158515 — intervention group
Group type: EXPERIMENTAL
Intervention: CalCarb graft material
Number of subjects: 20
Study 8158515 — intervention group
Group type: COMPARATOR
Intervention: DEBR (open flap debridement)
Number of subjects: 20
Study 3145557 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 72
Study 3145557 — intervention group
Group type: EXPERIMENTAL
Intervention: streptokinase i.v.
Number of subjects: 72
Study 3145557 — intervention group
Group type: EXPERIMENTAL
Intervention: thrombolytic therapy (overall)
Number of subjects: 72
Study 29480253 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric IOL with a capsular tension ring (CTR)
Number of subjects: 50
Study 29480253 — intervention group
Group type: COMPARATOR
Intervention: Toric IOL without a capsular tension ring (CTR)
Number of subjects: 50
Study 28401417 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive educational program (public lectures, instructional brochures, case videos, simulations, role-playing)
Number of subjects: 220
Study 28401417 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral education (control group)
Number of subjects: 220
Study 25973985 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 58
Study 25973985 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 58
Study 23311722 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 21881932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-lidocaine-tourniquet (SLT)
Number of subjects: 100
Study 21881932 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (S)
Number of subjects: 100
Study 21881932 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (L)
Number of subjects: 100
Study 21881932 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-lidocaine (SL)
Number of subjects: 100
Study 21881932 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine-tourniquet (LT)
Number of subjects: 100
Study 19085261 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg/day
Number of subjects: 83
Study 19085261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 83
Study 16831981 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide (Nt-proBNP)
Number of subjects: 3199
Study 16831981 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble intercellular adhesion molecule-1
Number of subjects: 3199
Study 16831981 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 3199
Study 16831981 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble interleukin-1 receptor antagonist
Number of subjects: 3199
Study 16831981 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 3199
Study 12624579 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise group (LEX; 50% 1-repetition maximum; 13 repetitions per exercise)
Number of subjects: 62
Study 12624579 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise group (HEX; 80% 1-repetition maximum; eight repetitions per exercise)
Number of subjects: 62
Study 12624579 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 10587386 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 66
Study 10587386 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 66
Study 9590863 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamox administered preoperatively
Number of subjects: 58
Study 9590863 — intervention group
Group type: COMPARATOR
Intervention: Mannitol or no drugs administered preoperatively
Number of subjects: 58
Study 9590863 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative IOP measurements
Number of subjects: 58
Study 1920306 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with SAARD therapy
Number of subjects: 83
Study 1920306 — intervention group
Group type: COMPARATOR
Intervention: Delayed initiation of SAARD therapy
Number of subjects: 83
Study 6122937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg once daily
Number of subjects: 1456
Study 6122937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1456
Study 6122937 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta adrenoceptor blocking drugs
Number of subjects: 1456
Study 30519893 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime bolus-continuous infusion targeting free serum cefuroxime concentrations of 64 mg/L
Number of subjects: 196
Study 30519893 — intervention group
Group type: COMPARATOR
Intervention: Standard bolus dose of cefuroxime (1.5 g bolus dose four-hourly)
Number of subjects: 196
Study 28120603 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nebulized budesonide (1 mg twice daily)
Number of subjects: 0
Study 28120603 — intervention group
Group type: COMPARATOR
Intervention: Systemic steroid therapy (prednisolone 0.5 mg/kg iv three times daily)
Number of subjects: 0
Study 28120603 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nebulized budesonide
Number of subjects: 0
Study 28120603 — intervention group
Group type: COMPARATOR
Intervention: Systemic steroid therapy
Number of subjects: 0
Study 26591686 — intervention group
Group type: EXPERIMENTAL
Intervention: Yi Zhi Chan Tuina manipulation with vertical force of 9.31 N for 10 min
Number of subjects: 45
Study 26591686 — intervention group
Group type: COMPARATOR
Intervention: Yi Zhi Chan Tuina manipulation with 2 min treatment time
Number of subjects: 45
Study 26591686 — intervention group
Group type: COMPARATOR
Intervention: Yi Zhi Chan Tuina manipulation with light force
Number of subjects: 45
Study 26591686 — intervention group
Group type: EXPERIMENTAL
Intervention: Yi Zhi Chan Tuina manipulation with medium force
Number of subjects: 45
Study 26591686 — intervention group
Group type: COMPARATOR
Intervention: Yi Zhi Chan Tuina manipulation with heavy force
Number of subjects: 45
Study 23131063 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic catheter ablation (RNS)
Number of subjects: 258
Study 23131063 — intervention group
Group type: COMPARATOR
Intervention: Manual catheter ablation
Number of subjects: 258
Study 21552645 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg)
Number of subjects: 21
Study 21552645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 18471515 — intervention group
Group type: EXPERIMENTAL
Intervention: IC41 vaccine (3 different dose groups)
Number of subjects: 60
Study 18471515 — intervention group
Group type: COMPARATOR
Intervention: HCV peptides alone
Number of subjects: 60
Study 18471515 — intervention group
Group type: EXPERIMENTAL
Intervention: IC41 vaccine
Number of subjects: 60
Study 16927534 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of lithium carbonate 300 mg
Number of subjects: 24
Study 12782436 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg morphine sulfate applied topically to the ulcer
Number of subjects: 5
Study 12782436 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water for injection) applied topically to the ulcer
Number of subjects: 5
Study 10947689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous epinephrine (15 microg)
Number of subjects: 8
Study 8976314 — intervention group
Group type: EXPERIMENTAL
Intervention: Curl-up (CU) exercise
Number of subjects: 33
Study 8976314 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior pelvic tilt (PT) exercise
Number of subjects: 33
Study 1832340 — intervention group
Group type: EXPERIMENTAL
Intervention: Yipanzhu decoction (YD)
Number of subjects: 40
Study 1832340 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 40
Study 6581064 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol powder (0.2 mg)
Number of subjects: 10
Study 6581064 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol aerosol (0.2 mg)
Number of subjects: 10
Study 3780693 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin pretreatment
Number of subjects: 0
Study 3780693 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid pretreatment
Number of subjects: 0
Study 3780693 — intervention group
Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 0
Study 31094639 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR)
Number of subjects: 19
Study 31094639 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study 29310718 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 100
Study 29310718 — intervention group
Group type: COMPARATOR
Intervention: Eye Movement Desensitisation Reprocessing (EMDR)
Number of subjects: 100
Study 26613821 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program based on the PRECEDE model
Number of subjects: 48
Study 26613821 — intervention group
Group type: COMPARATOR
Intervention: Routine interventions (Control)
Number of subjects: 48
Study 24962478 — intervention group
Group type: EXPERIMENTAL
Intervention: VRAM perineal reconstruction (Group A)
Number of subjects: 60
Study 24962478 — intervention group
Group type: COMPARATOR
Intervention: Primary perineal wound closure (Group B)
Number of subjects: 60
Study 22669347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl 2 μg/kg with IV and IM saline placebo
Number of subjects: 171
Study 22669347 — intervention group
Group type: EXPERIMENTAL
Intervention: IV morphine 0.1 mg/kg with nasal and IM placebo
Number of subjects: 171
Study 22669347 — intervention group
Group type: EXPERIMENTAL
Intervention: IM morphine 0.1 mg/kg with nasal and IV placebo
Number of subjects: 171
Study 22669347 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 171
Study 20511615 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly for 12 weeks
Number of subjects: 40
Study 20511615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18201659 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial injection of corticosteroids, local anesthetic, and contrast dye from anterolateral, lateral, or posterior locations
Number of subjects: 60
Study 18201659 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial injection of corticosteroids, local anesthetic, and contrast dye
Number of subjects: 60
Study 16025045 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection immunotherapy
Number of subjects: 42
Study 16025045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal steroid use
Number of subjects: 42
Study 12844093 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous technique (group A)
Number of subjects: 30
Study 12844093 — intervention group
Group type: COMPARATOR
Intervention: Conventional cutdown (group B)
Number of subjects: 30
Study 10585359 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cystatin C
Number of subjects: 30
Study 8946098 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth guards (30% dry w/w chlorhexidine)
Number of subjects: 11
Study 8946098 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chlorhexidine)
Number of subjects: 11
Study 2013139 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous balloon commissurotomy
Number of subjects: 40
Study 2013139 — intervention group
Group type: COMPARATOR
Intervention: Surgical closed commissurotomy
Number of subjects: 40
Study 6275811 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine hydrochloride or decanoate
Number of subjects: 28
Study 6275811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6275811 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up (mean interval, 3.5 years)
Number of subjects: 28
Study 6275811 — intervention group
Group type: EXPERIMENTAL
Intervention: Original sample
Number of subjects: 28
Study 30683426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocurcumin
Number of subjects: 50
Study 30683426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30304425 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate pushing (n=1200)
Number of subjects: 2414
Study 30304425 — intervention group
Group type: COMPARATOR
Intervention: Delayed pushing (n=1204)
Number of subjects: 2414
Study 30304425 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate pushing
Number of subjects: 2414
Study 30304425 — intervention group
Group type: COMPARATOR
Intervention: Delayed pushing
Number of subjects: 2414
Study 27410922 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg orally daily on days 1 through 4
Number of subjects: 380
Study 27410922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 25269863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural Raising Healthy Children intervention (12 sessions)
Number of subjects: 100
Study 25269863 — intervention group
Group type: COMPARATOR
Intervention: No intervention (usual care)
Number of subjects: 100
Study 22900785 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine (≤266 mg)
Number of subjects: 9
Study 22900785 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine HCl (≤200 mg)
Number of subjects: 9
Study 19887625 — intervention group
Group type: EXPERIMENTAL
Intervention: Baltimore Healthy Stores (BHS) intervention
Number of subjects: 84
Study 19887625 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group of eight stores)
Number of subjects: 84
Study 19887625 — intervention group
Group type: EXPERIMENTAL
Intervention: BHS shelf label presence
Number of subjects: 84
Study 17985974 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative wound care strategies (SPECIAL approach)
Number of subjects: 0
Study 16234044 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500 mg (tablet) for patients aged 12 years or older, 200 mg (oral suspension) for patients aged 4-11 years, 100 mg (oral suspension) for patients aged 1-3 years, administered twice daily for 3 days.
Number of subjects: 84
Study 16234044 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 84
Study 16234044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 11399693 — intervention group
Group type: EXPERIMENTAL
Intervention: Second pulmonary rehabilitation program (PRP2)
Number of subjects: 61
Study 11399693 — intervention group
Group type: EXPERIMENTAL
Intervention: Third pulmonary rehabilitation program (PRP3)
Number of subjects: 61
Study 11399693 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly hospitalizations and exacerbations
Number of subjects: 61
Study 11399693 — intervention group
Group type: COMPARATOR
Intervention: Yearly exacerbations
Number of subjects: 61
Study 11399693 — intervention group
Group type: COMPARATOR
Intervention: Health-related quality of life (HRQL)
Number of subjects: 61
Study 9413466 — intervention group
Group type: COMPARATOR
Intervention: Danaparoid sodium (750 anti-Xa units once a day for 6 weeks)
Number of subjects: 9
Study 7954760 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral lysine acetylsalicylate and metoclopramide (LAS-MCP) 1620 mg lysine acetylsalicylate (equivalent to 900 mg aspirin) combined with 10 mg metoclopramide
Number of subjects: 266
Study 7954760 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral lysine acetylsalicylate and metoclopramide (LAS-MCP)
Number of subjects: 266
Study 3653766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 60 mg/m2 every 3 weeks
Number of subjects: 30
Study 3653766 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide, doxorubicin, and cisplatin (CAP) 400 mg/m2, 40 mg/m2, and 40 mg/m2 respectively every 4 weeks
Number of subjects: 30
Study 3653766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 500 mg/m2 plus doxorubicin 40 mg/m2 every 3 weeks (secondary treatment)
Number of subjects: 30
Study 3653766 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CDDP)
Number of subjects: 30
Study 3653766 — intervention group
Group type: COMPARATOR
Intervention: Combination of cyclophosphamide, doxorubicin, and cisplatin (CAP)
Number of subjects: 30
Study 31390458 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual psycho-educational counseling (2 sessions)
Number of subjects: 44
Study 31390458 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 27267974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI)
Number of subjects: 9
Study 27267974 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-exercise cooling by intermittent facial water spray (SPRAY)
Number of subjects: 9
Study 27267974 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9
Study 25885677 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (40 mg daily for 5 days)
Number of subjects: 436
Study 25885677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436
Study 22845184 — intervention group
Group type: EXPERIMENTAL
Intervention: Written plus oral information before colonoscopy
Number of subjects: 0
Study 22845184 — intervention group
Group type: COMPARATOR
Intervention: Oral information before colonoscopy
Number of subjects: 0
Study 21266792 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA, 10 mg/day)
Number of subjects: 82
Study 21266792 — intervention group
Group type: EXPERIMENTAL
Intervention: Lynestrenol (LYN, 15 mg/day)
Number of subjects: 82
Study 21266792 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone (NET, 15 mg/day)
Number of subjects: 82
Study 19453719 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) treatment
Number of subjects: 46
Study 19453719 — intervention group
Group type: EXPERIMENTAL
Intervention: Termination of VPA treatment
Number of subjects: 46
Study 16885729 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 48
Study 16885729 — intervention group
Group type: COMPARATOR
Intervention: Unipolar electrocautery tonsillectomy
Number of subjects: 48
Study 14739892 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop (Strong pH)
Number of subjects: 24
Study 14739892 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Up Bond F (Intermediate pH)
Number of subjects: 24
Study 14739892 — intervention group
Group type: EXPERIMENTAL
Intervention: ScotchBond Multi‐Purpose (separate etchant and primer)
Number of subjects: 24
Study 11777668 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone and group therapy (12-week double-blind placebo-controlled trial)
Number of subjects: 50
Study 11777668 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12-week double-blind placebo-controlled trial)
Number of subjects: 50
Study 8988693 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid application of vacuum
Number of subjects: 47
Study 8988693 — intervention group
Group type: COMPARATOR
Intervention: Stepwise application of vacuum
Number of subjects: 47
Study 8424014 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine anesthesia (0.2 to 0.5 mL)
Number of subjects: 100
Study 8424014 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lidocaine)
Number of subjects: 100
Study 8424014 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine anesthesia
Number of subjects: 100
Study 8424014 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 8424014 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine anesthesia and Control group
Number of subjects: 100
Study 3301232 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine
Number of subjects: 48
Study 3301232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31427273 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory continuous theta‐burst repetitive transcranial magnetic stimulation (cTBS)
Number of subjects: 0
Study 31427273 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 0
Study 28741383 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) adherence intervention
Number of subjects: 163